Bariatric Arterial Embolization for Morbid Obesity

Overview

The purpose of this study is to evaluate the safety and effectiveness of left gastric artery embolization(bariatric arterial embolization) for morbid obesity. When the target vessel is blocked, some of the body's signals for feeling hungry will be suppressed and lead to weight loss. Although there are many ways to treat morbid obesity, surgery is currently the only effective method to be confirmed. But surgical treatment is likely to carry a high risk of treatment-related complications, such as fistula or intestinal obstruction, etc. This study is designed to help treat obesity using a method of transvascular interventional therapy, which is minimally invasive and non-surgical.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2017

Interventions

  • Procedure: left gastric artery embolization
  • Behavioral: healthy diet and exercise

Arms, Groups and Cohorts

  • Experimental: left gastric artery embolization
    • Patients undergoing left gastric artery embolization
  • Active Comparator: healthy diet and exercise
    • Patients undergoing healthy diet and exercise

Clinical Trial Outcome Measures

Primary Measures

  • Weight Loss
    • Time Frame: Baseline, post-op 1 month, 3 months, 6 months,9 months,12 months
    • Unit of Measure: Percentage of excess weight loss [%EWL]. The body weight will be measured within 2-4h after breakfast.

Secondary Measures

  • Blood pressure
    • Time Frame: Baseline, post-op 1 month, 3 months, 6 months,9 months,12 months
    • The brachial artery blood pressure will be measured in the early hours of the morning and under the quiet situation. Unit of Measure: mmHg.
  • Lipid Profile
    • Time Frame: Baseline, post-op 1 month, 3 months, 6 months,9 months,12 months
    • Blood cholesterol levels, triglyceride levels and lipoprotein levels will be detected. Unit of Measure: mmol/L.
  • Number of Patients with Adverse Events
    • Time Frame: post-op 30 days
    • Surgical complications and adverse events such as massive hemorrhage, femoral artery pseudoaneurysm, gastric mucosal ischemia and necrosis and gastric perforation, etc., will be documented.
  • Ghrelin levels
    • Time Frame: Baseline, post-op 1 month, 3 months, 6 months,9 months,12 months
    • Unit of Measure: pg/mL. Detection of serum Ghrelin levels will be obtained using fasting blood in the morning.
  • Abdominal fat content
    • Time Frame: Baseline, post-op 1 month,6 months,12 months
    • Abdominal fat content detected by MRI.
  • Leptin levels
    • Time Frame: Baseline, post-op 1 month, 3 months, 6 months,9 months,12 months
    • Detection of serum Leptin levels will be obtained using fasting blood in the morning. Unit of Measure: pg/mL.
  • Results of Gastroendoscopic Examination
    • Time Frame: Baseline, post-op 1 week, post-op 1 month, 3 months, 6 months,9 months,12 months
    • Photos and clinical reports will be analyzed.
  • Quality of Life Parameters Survey
    • Time Frame: 12 months
    • N/A Utilizing SF-36/ pre and post procedure to determine the changes of quality in life; everyday activities.

Participating in This Clinical Trial

Inclusion Criteria

1. Body mass index (BMI) >30. 2. No history of gastrointestinal surgery. 3. Willing, able and mentally competent to provide written informed consent. 4. Suitable for protocol therapy as determined by the interventional radiology Investigator. 5. Adequate hematological, hepatic and renal function as follows: Hematological Neutrophils > 1.5 x 109/L Platelets > 100 x 109/L INR <1.5 Hepatic Bilirubin ≤ 2.0 mg/dL Albumin ≥ 2.5 g/L Renal Estimated GFR > 60ml/min.1.73m2 6. Aged between18 and 65 years old. 7. More than one year's follow-up can be obtained reliably Exclusion Criteria:

1. Prior history of gastric pancreatic, hepatic, and/or splenic surgery 2. Prior embolization to the stomach, spleen or liver 3. Prior or current history of peptic ulcer disease 4. Significant risk factors for peptic ulcer disease including daily NSAID use and smoking. 5. Portal venous hypertension or cirrhosis 6. Less than 18 years or older than 65 years of age 7. Known aortic pathology such as aneurysm or dissection renal insufficiency as evidenced by an estimated glomerular filtration rate of < 60 milliliters per minute an estimated glomerular filtration rate of < 60 milliliters per minute 8. Major comorbidity such as cancer, significant cardiovascular disease, or peripheral arterial disease 9. Pregnant or intend to become pregnant within one year Known history of allergy to iodinated contrast media 10. Patients with certain psychiatric disorders such as schizophrenia, borderline personality disorder, and uncontrolled depression, and mental/cognitive impairment that limits the individual's ability to understand the proposed therapy. 11. Patients currently taking or requiring chronic use of NSAID or steroid medications

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Zhongda Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Gao-jun Teng, Professor of Radiology & Chair,Department of Radiology – Zhongda Hospital
  • Overall Official(s)
    • Gao-jun Teng, Ph.D,MD, Principal Investigator, Zhongda Hospital
  • Overall Contact(s)
    • Zhibin Bai, baizhibin1004@sina.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.